Compare · CNC vs PSNL
CNC vs PSNL
Side-by-side comparison of Centene Corporation (CNC) and Personalis Inc. (PSNL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and PSNL operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.26B, about 32.1x PSNL ($1.01B).
- Over the past year, CNC is up 18.2% and PSNL is up 64.1% - PSNL leads by 45.9 points.
- PSNL has been more active in the news (11 items in the past 4 weeks vs 8 for CNC).
- CNC has more recent analyst coverage (25 ratings vs 14 for PSNL).
- Company
- Centene Corporation
- Personalis Inc.
- Price
- $65.33-1.28%
- $9.60-1.59%
- Market cap
- $32.26B
- $1.01B
- 1M return
- +15.94%
- +65.52%
- 1Y return
- +18.22%
- +64.10%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 14
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Personalis Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Latest CNC
- Home State Health, Centene Foundation Announce $750,000 Grant Opportunity for Missouri Organizations Improving Health Outcomes
- Long Beach Community Care Campus Expansion Advances with $10 Million Investment from Centene Foundation and Health Net
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Centene upgraded by Deutsche Bank with a new price target
- New insider Finke Daniel P claimed ownership of 228,127 shares (SEC Form 3)
- New insider Carson Michael A claimed ownership of 123,707 shares (SEC Form 3)
- Centene Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- Director Tanji Kenneth was granted 3,992 shares, increasing direct ownership by 50% to 11,909 units (SEC Form 4)
Latest PSNL
- Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
- CFO AND COO Tachibana Aaron exercised 40,000 shares at a strike of $9.16 and sold $480,400 worth of shares (40,000 units at $12.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
- Chief Executive Officer Hall Christopher M sold $1,102,000 worth of shares (100,000 units at $11.02) as part of a pre-agreed trading plan and exercised 100,000 shares at a strike of $1.61 (SEC Form 4)
- CFO AND COO Tachibana Aaron sold $449,292 worth of shares (38,799 units at $11.58) as part of a pre-agreed trading plan and exercised 38,799 shares at a strike of $9.16 (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- SEC Form 144 filed by Personalis Inc.
- Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
- Personalis Inc. filed SEC Form 8-K: Other Events